Massive study reveals how “hypermutated” malignant brain tumors with many mutations escape chemotherapy and immunotherapy
Dana-Farber Cancer InstituteAn analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.